Elevated levels of oxidative stress in tamoxifen resistant breast cancer have been previously reported [27], which we postulate may correlate with increased PARP1 expression and activity, implicating PARP1 as a therapeutic target to overcome tamoxifen resistance [19,20]. Here, PARP1 is linked to breast carcinoma.